Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $20.40

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given an average recommendation of “Buy” by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.40.

A number of research firms have weighed in on ARTV. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Wedbush reiterated an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald cut their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 25th.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $1.98 on Wednesday. The business has a 50 day moving average price of $3.90 and a 200 day moving average price of $8.45. Artiva Biotherapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $17.31.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG purchased a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at about $216,000. BNP Paribas Financial Markets raised its stake in Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after acquiring an additional 7,151 shares during the last quarter. Northern Trust Corp raised its stake in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after acquiring an additional 4,335 shares during the last quarter. Barclays PLC lifted its position in Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after purchasing an additional 3,361 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.